RT - European Journal of Gynaecological Oncology ID - 10.31083/j.ejgo.2021.02.2288 T1 - Prognostic factors in patients with recurrent ovarian cancer treated with radiation therapy A1 - Nobuaki Kosaka A1 - Kiyoshi Hasegawa A1 - Kaori Kiuchi A1 - Emi Motegi A1 - EYasuo Ejima K1 - Recurrent ovarian cancer; Radiation therapy; Curative-intent RT; Palliative RT; Prognostic factors YR - 2021 SP - 311 AB -

Objectives: Radiation therapy (RT) for recurrent ovarian cancer may be considered not only for palliation of symptoms, but also to prolong survival in selected patients. Herein, we investigated the efficacy of RT and associated prognostic factors. Methods: The relationship between clinicopathological factors including age, PS, FIGO stage at initial diagnosis, histological type, number of relapsed lesions (solitary or multiple), aim of RT (curative or palliative intent), and treatment-free interval (TFI) and progression-free survival (PFS) and overall survival (OS) was investigated in 17 patients with recurrent ovarian cancer treated with RT. Results: The median age was 58.5 years. Eight patients (three with solitary and five with multiple relapsed lesions) were treated with curative-intent RT, and nine patients (all with multiple relapsed lesions) were treated with palliative RT. Response to RT was as follows: CR: 3 patients, PR: 5 patients, SD: 3 patients, and PD: 6 patients. The response rate (CR + PR) and disease control rate (CR + PR + SD) were 47.1% and 64.7%, respectively; neither were associated with TFI. The 2-year PFS and OS rates after RT were 11.8% and 29.4%, respectively. In univariate analysis, solitary relapsed lesions and curative-intent RT were judged as favorable prognostic factors for PFS and OS. However, in multivariate analysis, only curative-intent RT was identified as an independent favorable prognostic factor for OS (hazard ratio: 3.65, 95% confidence interval: 1.03–12.00, P = 0.045). Conclusions: This retrospective study indicated that curative-intent RT may be an effective treatment method for patients when clinically indicated, regardless of whether recurrent tumors are sensitive to chemotherapy.